| Jin, Hui M |
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects |
|
|
| Not yet recruiting | 3 | 408 | RoW | TQF3510 (Semaglutide Injection), Wegovy® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Obesity | 07/26 | 08/26 | | |
NCT04399564: Temporary vs.Long Term Hemodialysis Catheter on Central Vein Stenosis |
|
|
| Not yet recruiting | N/A | 80 | NA | temporary hemodialysis catheters, long-term hemodialysis catheters | Shanghai Pudong Hospital | Stenosis of Arteriovenous Dialysis Fistula | 06/21 | 06/21 | | |
| Not yet recruiting | N/A | 230 | NA | active comarator using antiviral drug of nucleoside analogues, HA+purification | Shanghai Pudong Hospital | Chronic Hepatitis b | 09/23 | 09/23 | | |
| Zhu, Haidong |
| Recruiting | 1 | 40 | US | Salt pills, Placebo pills | Augusta University | High Blood Pressure | 12/22 | 12/22 | | |
NCT04520906: To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer |
|
|
| Recruiting | N/A | 139 | RoW | microwave ablation | Suzhou Hengruihongyuan Medical Technology Co. LTD | Hepatocellular Carcinoma | 01/23 | 12/23 | | |
| Active, not recruiting | N/A | 188 | RoW | Camrelizumab, TACE, Apatinib | Zhongda Hospital | Hepatocellular Carcinoma | 08/24 | 01/26 | | |
| Teng, Gao-Jun |
NCT05073744: Nalbuphine Versus Morphine for Perioperative Tumor Ablation |
|
|
| Recruiting | 4 | 316 | RoW | Nalbuphine, Tumor ablation using nalbuphine, Morphine, Tumor ablation using morphine | Zhongda Hospital | Nalbuphine Allergy, Ablation, Safety | 08/23 | 08/23 | | |
NCT05912686: High-Dose Atorvastatin for Vascular Wall Protection in Thrombectomy Patients |
|
|
| Not yet recruiting | 4 | 162 | RoW | Atorvastatin 80mg, Atorvastatin 20mg | Zhongda Hospital | Mechanical Thrombectomy, Acute Ischemic Stroke | 12/25 | 07/26 | | |
NCT05472896: TACE With Dicycloplatin(TP21) in Unresectable HCC |
|
|
| Recruiting | 3 | 332 | RoW | cTACE, Dicycloplatin (TP21), Epirubicin | Gao-jun Teng | Hepatocellular Carcinoma | 06/24 | 06/24 | | |
NCT05344924: TACE Combined With Penpulimab and Anlotinib for Advanced HCC |
|
|
| Recruiting | 2/3 | 109 | RoW | TACE+penpulimab+anlotinib vs. penpulimab+anlotinib, The combination of penpulimab+anlotinib with or without TACE | Zhongda Hospital | Hepatocellular Carcinoma | 03/23 | 03/24 | | |
NCT05280444: Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma |
|
|
| Recruiting | 2/3 | 216 | RoW | Idarubicin Hydrochloride for Injection, Anbijian | Zhongda Hospital | Hepatocellular Carcinoma | 06/23 | 07/23 | | |
| Recruiting | 2 | 72 | RoW | Tislelizumab in combination with cTACE, BGB-A317 | Zhongda Hospital | Hepatocellular Carcinoma | 11/22 | 11/23 | | |
| Recruiting | 2 | 32 | RoW | HAIC combined with donafenib and sintilimab, HAIC-donafenib-sintilimab | Zhongda Hospital | Cholangiocarcinoma | 06/23 | 07/23 | | |
| Recruiting | 1/2 | 60 | RoW | Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres | Zhongda Hospital | Unresectable Colorectal Liver Metastases | 12/24 | 12/24 | | |
NCT05957640: Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | Yttrium-90 carbon microspheres SIRT | Zhongda Hospital | Unresectable Hepatocellular Carcinoma | 05/25 | 05/25 | | |
| Completed | N/A | 826 | RoW | TACE+ICIs, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 05/22 | 02/23 | | |
NCT04060797: Endovascular Denervation Improves Limb Ischemia in Patients With Peripheral Artery Disease |
|
|
| Completed | N/A | 38 | RoW | endovascular denervation, PTA | Zhongda Hospital | PAD | 09/21 | 09/21 | | |
| Recruiting | N/A | 30 | RoW | Endovascular Denervation | Zhongda Hospital | Type 2 Diabetes Mellitus | 09/22 | 12/22 | | |
NCT05703750: Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301) |
|
|
| Recruiting | N/A | 228 | RoW | TACE ± Systemic therapy | Zhongda Hospital | Hepatocellular Carcinoma, Portal Hypertension | 06/23 | 12/23 | | |
NCT05704192: CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302) |
|
|
| Recruiting | N/A | 373 | RoW | TACE ± Systemic therapy | Zhongda Hospital | Hepatocellular Carcinoma, Portal Hypertension | 06/23 | 12/23 | | |
| Recruiting | N/A | 474 | RoW | PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 08/23 | 08/23 | | |
NCT05631561: Endovascular Denervation for the Treatment of Type 2 Diabetes Mellitus |
|
|
| Active, not recruiting | N/A | 30 | RoW | Endovascular denervation System (Generator and Catheter ) | Shanghai Golden Leaf MedTec Co. Ltd | Type 2 Diabetes Mellitus (T2DM) | 04/24 | 02/25 | | |
CHANCE2202, NCT05332496: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC |
|
|
| Recruiting | N/A | 220 | RoW | PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 08/23 | 09/23 | | |
| Active, not recruiting | N/A | 188 | RoW | Camrelizumab, TACE, Apatinib | Zhongda Hospital | Hepatocellular Carcinoma | 08/24 | 01/26 | | |
NCT06195917: Robotic-assisted Percutaneous Transhepatic Puncture |
|
|
| Recruiting | N/A | 20 | RoW | Robotic-assisted Interventional Percutaneous transhepatic puncture | Zhongda Hospital | Liver Diseases | 04/24 | 05/24 | | |
CHANCE023, NCT06024252: Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study |
|
|
| Not yet recruiting | N/A | 200 | NA | TACE, Atezolizumab, Bevacizumab | Zhongda Hospital | HCC | 12/23 | 06/24 | | |
NCT06190665: DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC |
|
|
| Recruiting | N/A | 188 | RoW | DEB-TACE with visualable microspheres, DEB-TACE with PVA microspheres | Zhongda Hospital | Hepatocellular Carcinoma | 12/25 | 12/26 | | |
ST-Y90-CP01, NCT06447727: Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM |
|
|
| Recruiting | N/A | 30 | RoW | SIRT with Yttrium-90 Microspheres, FOLFIRI and Bevacizumab | Zhongda Hospital | Colorectal Cancer Metastatic | 11/25 | 11/25 | | |
NCT06607120: Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies |
|
|
| Recruiting | N/A | 950 | RoW | | Zhongda Hospital | Hepatocellular Carcinoma | 01/25 | 03/25 | | |
NCT06593964: TACE With Thermosensitive Nanogel Versus Embosphere for HCC |
|
|
| Recruiting | N/A | 188 | RoW | Thermosensitive Nanogel Embolic Agent | Zhongda Hospital | Unresectable Hepatocellular Carcinoma | 04/26 | 04/26 | | |
NCT05956860: Radial Access for Abdominopelvic Vascular Intervention |
|
|
| Recruiting | N/A | 1143 | RoW | abdominopelvic vascular intervention through the radial artery access | Zhongda Hospital, Terumo Medical Corporation | Vascular Access Device Complications | 12/24 | 12/25 | | |
EDPAD, NCT05345431: Endovascular Denervation for the Treatment of Patients With Peripheral Arterial Disease |
|
|
| Recruiting | N/A | 54 | RoW | endovascular denervation, PTA | Zhongda Hospital | PAD | 06/25 | 06/26 | | |
NCT06021015: Safety and Efficacy of Polyvinyl Alcohol Sodium Acrylate Embolization Microspheres for CRLM |
|
|
| Not yet recruiting | N/A | 72 | NA | Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）, Irinotecan and HepaSphere Microspheres | Zhongda Hospital | Colorectal Cancer Liver Metastasis | 06/25 | 12/25 | | |
CHANCEsub, NCT05278195: Assessing the Prognosis of TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for HCC by Using Clinical and Imaging Biomarkers |
|
|
| Recruiting | N/A | 300 | RoW | | Zhongda Hospital | Hepatocellular Carcinoma | 12/22 | 12/23 | | |
| Qiu, Haibo |
NCT02654561: Efficacy and Safety of Unfractionated Heparin on Severe Sepsis With Suspected Disseminated Intravascular Coagulation |
|
|
| Recruiting | 3 | 600 | RoW | Heparin Sodium, Unfractionated heparin, Saline, Normal saline | China Medical University, China, West China Hospital, Zhongda Hospital, The First Affiliated Hospital of Dalian Medical University, Shengjing Hospital, The First Hospital of Jilin University, Qilu Hospital of Shandong University, The Second Affiliated Hospital of Kunming Medical University, The First Hospital of Qinhuangdao, The Second Affiliated Hospital of Dalian Medical University, First Affiliated Hospital of Harbin Medical University, Peking University People's Hospital, The People's Hospital of Liaoning Province, Fourth People's Hospital of Shenyang, Beijing Tsinghua Changgeng Hospital, First Affiliated Hospital of Kunming Medical University, The Affiliated Hospital of Qingdao University, Beijing Friendship Hospital, General Hospital of Ningxia Medical University, The First Affiliated Hospital of Nanchang University | Sepsis, Disseminated Intravascular Coagulation | 12/24 | 06/25 | | |
| Recruiting | 2 | 53 | RoW | Tislelizumab, Oxaliplatin, S-1, Capecitabine | Sun Yat-sen University | Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach | 11/24 | 11/27 | | |
NCT05000671: A Study to Evaluate the Safety and Effect of STC314 Injection Continuous Infusion in Subjects With Acute Respiratory Distress Syndrome |
|
|
| Recruiting | 1 | 16 | RoW | STC314 injection or Placebo(rate=58.3 mg/hr), STC314 injection or Placebo(rate=87.5 mg/hr) | Grand Medical Pty Ltd., Grand Pharmaceutical (China) Co., Ltd. | Acute Respiratory Distress Syndrome | 12/22 | 12/22 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
| Recruiting | N/A | 210 | RoW | blood mNGS (IDSeqTM Ultra); blood Culture | Southeast University, China, The First Affiliated Hospital with Nanjing Medical University, Northern Jiangsu Province People's Hospital | Sepsis | 12/22 | 12/22 | | |
NCT05677984: Awaken Prone Positioning Ventinlation in COVID-19 Patients |
|
|
| Completed | N/A | 409 | RoW | Awaken prone positioning ventilation | Southeast University, China | COVID-19 | 04/23 | 05/23 | | |
| Completed | N/A | 10 | RoW | different modes of mechanical ventilation | Southeast University, China | Acute Respiratory Failure | 08/23 | 08/23 | | |
NCT03345758: Long Term Outcome of Extracorporeal Membrane Oxygenation Patients in China |
|
|
| Recruiting | N/A | 80 | RoW | outcome | Southeast University, China | Long-term Outcome, Extracorporeal Membrane Oxygenation | 12/23 | 12/23 | | |
NCT03763890: Post- End- Expiratory Pressure Affect the Alveolar Heterogeneity in Moderate and Sever ARDS Patients |
|
|
| Recruiting | N/A | 40 | RoW | Post-end-Expiratory pressure | Southeast University, China | Ards | 12/23 | 12/23 | | |
NCT03182023: Long-term Outcome of Patients Treated With Extracorporeal Membrane Oxygenation |
|
|
| Recruiting | N/A | 83 | RoW | | Southeast University, China | Long-term Outcome, Extracorporeal Membrane Oxygenation | 12/23 | 12/23 | | |
| Wu, Gang |
Circular, NCT05411705: Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury |
|
|
| Recruiting | 4 | 165 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Control, No intervention | The First Affiliated Hospital of Dalian Medical University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Anqing Municipal Hospital, Henan Cancer Hospital, Wuhan Union Hospital, China, Peking University Shougang Hospital, Chinese PLA General Hospital, Liaoning Tumor Hospital & Institute, Tianjin Medical University Cancer Institute and Hospital, Henan Provincial People's Hospital, Shanxi Provincial Cancer Hospital, Beijing Sanhuan Cancer Hospital, Hebei Medical University Fourth Hospital, Tongji Hospital, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Bethune Charitable Foundation | Cancer Treatment Induced Thrombocytopenia | 06/24 | 08/24 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT02633176: Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 120 | RoW | Cetuximab, Erbitux, Cisplatin, Docetaxel, Taxotere, Capecitabine, Xeloda, Radiotherapy | Sun Yat-sen University, Chinese Southwest Oncology Group | Nasopharyngeal Carcinoma | 01/23 | | | |
Sepsis, NCT06548854: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploration Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Characteristics of STC314 Injection Administered Intravenously in Patients |
|
|
| Active, not recruiting | 2 | 180 | RoW | STC314 Injection/STC314 Injection Placebo, STC314 Injection Placebo | Grand Medical Pty Ltd. | Sepsis | 11/24 | 02/25 | | |
NCT03917043: APG-2449 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 150 | RoW | APG-2449, APG-2449 Capsule | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer, Malignant Pleural Mesothelioma | 01/25 | 02/25 | | |
NCT06127329: Efficacy and Safety of BAI Combined With DEB-BACE of EqualSpheres in the Treatment of Advanced NSCLC |
|
|
| Not yet recruiting | N/A | 70 | RoW | BAI combine with DEB-BACE | Gang Wu | Carcinoma, Non-Small Cell Lung | 12/24 | 12/26 | | |
| Chen, Ming |
HEARTRIP, NCT03809273: Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI |
|
|
| Recruiting | 4 | 668 | RoW | Yangxinshi, Trimetazidine, Yangxinshi mimic, Trimetazidine mimic | Shenyang Northern Hospital | Percutaneous Coronary Intervention | 12/20 | 12/20 | | |
NCT02111460: Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 3 | 126 | RoW | Loco-regional Radiotherapy | Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital | Nasopharyngeal Carcinoma | 08/19 | 12/22 | | |
| Recruiting | 3 | 315 | RoW | TQB2450, Anlotinib, TQB2450(blank), Anlotinib(blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Stage III Non-small-cell Lung Cancer | 12/22 | 03/25 | | |
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer |
|
|
| Active, not recruiting | 3 | 496 | Europe, US, RoW | Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 12/26 | 12/26 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
NCT04189094: Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC |
|
|
| Not yet recruiting | 2 | 140 | NA | Sintilimab, Etoposide, VP-16, Cisplatin, DDP, radiotherapy | Zhejiang Cancer Hospital, First Affiliated Hospital, Sun Yat-Sen University, The Affiliated Hospital of Guangdong Medical College, First People's Hospital of Foshan | Small Cell Lung Cancer Limited Stage | 07/21 | 07/23 | | |
| Recruiting | 2 | 26 | RoW | Rituximab, chidamide, lenalidomde | Zhejiang Cancer Hospital | Angioimmunoblastic T-cell Lymphoma, Chemotherapy Effect, Chemotherapeutic Toxicity | 03/22 | 12/22 | | |
CTV, NCT04543890: A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting s of the Primary Tumor in Limited SCLC |
|
|
| Recruiting | 2 | 300 | RoW | Hyperfractionated radiotherapy, Hypofractionated radiotherapy, Etoposide, VP-16, Cisplatin, DDP | Zhejiang Cancer Hospital, First Affiliated Hospital, Sun Yat-Sen University, Chinese PLA General Hospital, Guangdong Medical College | Small Cell Lung Cancer Limited Stage | 06/23 | 06/25 | | |
NCT05183958: A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer |
|
|
| Not yet recruiting | 2 | 118 | RoW | Radiotherapy group, Camrelizumab, Chemotherapy | Zhejiang Cancer Hospital, Zhejiang Provincial People's Hospital, The First Affiliated Hospital of Wenzhou Medical Univercity, Jinhua Municipal Central Hospital Medical Group, Lishui Municipal Central Hospital, The Affiliated People's hospital of Ningbo Univercity, Huizhou Municipal Central Hospital, People's Hospital of Quzhou, Sun Yet-sen Cancer Center | Esophageal Cancer | 12/23 | 12/25 | | |
NCT06472713: Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC |
|
|
| Recruiting | 2 | 32 | RoW | Mitoxantrone hydrochloride liposome injection, PD-1 Inhibitors | Ming-Yuan Chen | Recurrent or Metastatic Nasopharyngeal Carcinoma | 10/25 | 09/27 | | |
LOTS, NCT04999332: Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 () For Locally Advanced Gastric or Gastroesophageal Junction Cancer |
|
|
| Recruiting | 2 | 58 | RoW | leucovorin, oxaliplatin, docetaxel, S-1, leucovorin (Folina tab, TTY Biopharm, TW), oxaliplatin (Oxalip, TTY Biopharm, TW), docetaxel (Taxotere, Sanofi-Aventis, FR), S-1 (TS-1, Taiho, JP) | National Cheng-Kung University Hospital, TTY Biopharm, Kaohsiung Veterans General Hospital., Taipei Veterans General Hospital, Taiwan, China Medical University Hospital | Gastric Cancer, Gastric Adenocarcinoma, Effects of Chemotherapy, Toxicity Due to Chemotherapy | 12/24 | 12/25 | | |
NCT05651802: PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC Patients |
|
|
| Recruiting | N/A | 220 | RoW | Prophylactic cranial irradiation, Thoracic radiotherapy, Chemotherapy | Zhejiang Cancer Hospital, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Small Cell Lung Cancer Limited Stage | 12/25 | 06/26 | | |
| Teng, Gaojun |
AK104-308, NCT06371157: A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 3 | 469 | RoW | AK104, Lenvatinib, TACE, Placebo for AK104, Placebo for Lenvatinib | Akeso | Hepatocellular Carcinoma | 10/25 | 05/26 | | |
| Active, not recruiting | 3 | 92 | RoW | TheraSphere™ Yttrium-90 Glass Microspheres, conventional Transarterial Chemoembolization(cTACE) | Boston Scientific Corporation | Inoperable Hepatocellular Carcinoma | 02/26 | 10/26 | | |
| Recruiting | 1/2 | 60 | RoW | Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres | Zhongda Hospital | Unresectable Colorectal Liver Metastases | 12/24 | 12/24 | | |
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | NRT6003 Injection, Yttrium-90 carbon microspheres | Chengdu New Radiomedicine Technology Co. LTD. | Unresectable Hepatocellular Carcinoma | 10/25 | 10/25 | | |
NCT04520906: To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer |
|
|
| Recruiting | N/A | 139 | RoW | microwave ablation | Suzhou Hengruihongyuan Medical Technology Co. LTD | Hepatocellular Carcinoma | 01/23 | 12/23 | | |
NCT05673668: Endovascular Denervation (EDN) for the Treatment of Type 2 Diabetes Mellitus |
|
|
| Recruiting | N/A | 30 | RoW | Endovascular Denervation System (Netrod) | Zhongda Hospital | Type 2 Diabetes Mellitus (T2DM) | 10/23 | 04/24 | | |
NCT06669377: TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT. |
|
|
| Recruiting | N/A | 444 | RoW | | Zhongda Hospital | Hepatocellular Carcinoma | 01/25 | 03/25 | | |
NCT05956860: Radial Access for Abdominopelvic Vascular Intervention |
|
|
| Recruiting | N/A | 1143 | RoW | abdominopelvic vascular intervention through the radial artery access | Zhongda Hospital, Terumo Medical Corporation | Vascular Access Device Complications | 12/24 | 12/25 | | |
| Yang, Yi |
NCT04739592: A Study of Alendronate Sodium Vitamin D3 Tablets on Knee Osteoarthritis |
|
|
| Recruiting | 4 | 60 | RoW | alendronate sodium vitamin D3 tablets, Placebo | Peking Union Medical College Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Knee Osteoarthritis | 07/23 | 07/24 | | |
NCT06645522: Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke |
|
|
| Not yet recruiting | 4 | 1200 | RoW | Edaravone dexborneol, Placebo | Yi Yang | Acute Ischemic Stroke | 10/26 | 01/27 | | |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
NCT05745259: Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ） |
|
|
| Recruiting | 3 | 1630 | RoW | Alteplase, rt-PA, Tenecteplase, TNK-tPA | Beijing Tiantan Hospital, Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd, The Place Pharmaceutical(Jiangsu) Co., Ltd | Acute Ischemic Stroke | 11/23 | 03/24 | | |
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) |
|
|
| Recruiting | 3 | 510 | Europe, Canada, Japan, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 10/26 | 02/27 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
NCT04898322: SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis |
|
|
| Recruiting | 2a | 96 | RoW | SY-005, Placebo | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Sepsis | 07/23 | 07/23 | | |
NCT05865496: A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps |
|
|
| Active, not recruiting | 2 | 90 | RoW | 611, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Sinusitis, Nasal Polyps, Polyps | 05/24 | 07/24 | | |
NCT06664996: Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT |
|
|
| Recruiting | 2 | 33 | RoW | stereotactic body radiation therapy (SBRT), Sintilimab (approved) | West China Hospital | Hepatocellular Carcinoma (HCC) | 10/25 | 10/26 | | |
NCT05686642: Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke |
|
|
| Recruiting | 2 | 300 | RoW | LT3001 Drug:high dose, Placebo, LT3001 Drug:low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Acute Ischemic Stroke | 04/25 | 07/25 | | |
NCT06089278: A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps. |
|
|
| Recruiting | 2 | 160 | RoW | 300mg of TQH2722 injection, 600mg of TQH2722 injection, TQH2722 injection matching placebo | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Sinusitis | 05/25 | 05/25 | | |
NCT06038916: To Evaluate the Safety and Initial Efficacy of STSA-1002 Injection in Patients with Acute Respiratory Distress Syndrome |
|
|
| Recruiting | 1/2 | 60 | RoW | STSA-1002 Injection Placebo, STSA-1002 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Acute Respiratory Distress Syndrome | 08/25 | 09/26 | | |
NCT05590572: A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma |
|
|
| Not yet recruiting | 1/2 | 148 | RoW | Sulfatinib, Etoposide, Isophosphamide | Second Affiliated Hospital, School of Medicine, Zhejiang University, Chonnam National University, Peking University People's Hospital, Qilu Hospital of Shandong University, Ruijin Hospital, Shanghai Jiao Tong University Affiliated Sixth People's Hospital | Osteosarcoma | 12/26 | 12/27 | | |
NCT04536337: A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects |
|
|
| Recruiting | 1 | 336 | Europe, RoW | ALG-000184, Placebo, Entecavir | Aligos Therapeutics | Chronic Hepatitis B | 11/23 | 06/24 | | |
NCT04980625: Safety and Efficacy of Remote Ischemic Conditioning Combined With Intravenous Thrombolysis for Acute Ischemic Stroke |
|
|
| Completed | N/A | 558 | RoW | Remote ischemic conditioning, Sham remote ischemic conditioning | Yi Yang | Acute Ischemic Stroke | 05/23 | 05/23 | | |
CASCAS, NCT05028855: Cerebral Autoregulation in Patients With Symptomatic Cerebral Atherosclerotic Stenosis |
|
|
| Recruiting | N/A | 850 | RoW | Cerebral autoregulation assessment | Yi Yang, Shenzhen Second People's Hospital, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of University of South China, Eighth Affiliated Hospital, Sun Yat-sen University, The First Affiliated Hospital of Hebei North University, Qilu Hospital of Shandong University, The Affiliated Hospital of Qingdao University, The Affiliated Hospital of Yanbian University | Cerebrovascular Stroke, Cerebral Artery Stenosis | 12/25 | 08/26 | | |
| Recruiting | N/A | 3000 | RoW | Treatment following current guidelines | Yi Yang, Jiujiang No.1 People's Hospital, Dezhou People's Hospital, The Affiliated Hospital of Yanbian University, First Affilated Hospital of Jiamusi University, Xuchang Central Hospital, Inner Mongolia People's Hospital, Shaoxing People's Hospital, Chinese PLA General Hospital, General Hospital of Ningxia Medical University, General Hospital of Shenyang Military Region, Siping Central People's Hospital, The First Affilated Hospital of the Medical College, Shihezi University, Daqing Oilfieled General Hospital, Heilongjiang Provicial Hospital, The First Affiliated Hospital of Soochow University, Luoyang Central Hospital Affilated to Zhengzhou University, Wuzhou Red Cross Hospital, Cangzhou Central Hospital, Binzhou Medical University, Affilated Hospital of Inner Mongolia University for the Nationalities, Fudan University Pudong Medical Center | Ischemic Stroke | 12/24 | 07/25 | | |
SRICDCA-IVT, NCT05550103: Effect of Serial Remote Ischemic Conditioning on Dynamic Cerebral Autoregulation in Patients With Intravenous Thrombolysis |
|
|
| Recruiting | N/A | 60 | RoW | Remote ischemic conditioning, Sham remote ischemic conditioning, Standard medical treatment | Yi Yang | Acute Ischemic Stroke | 02/23 | 05/23 | | |
NCT05599009: Remote Ischemic Conditioning and Dynamic Cerebral Autoregulation in Patients With Intracranial and Extracranial Arteriosclerosis |
|
|
| Recruiting | N/A | 140 | RoW | remote ischemic conditioning, sham remote ischemic conditioning | The First Hospital of Jilin University | Carotid Stenosis, Ischemic Stroke | 02/23 | 02/23 | | |
ESCAPE-SVD, NCT05225948: Effects of Remote Ischemic Conditioning on Dynamic Cerebral Autoregulation, Blood Pressure and Heart Rate Variability in Patients With Cerebral Small Vessel Disease |
|
|
| Recruiting | N/A | 100 | RoW | Remote ischemic conditioning, Sham remote ischemic conditioning | Yi Yang | Cerebral Small Vessel Diseases | 07/25 | 10/25 | | |
NCT04541758: Comparing the Efficacy of Conservative Treatment With Minimally Invasive Surgery in the Treatment of Rib Fractures |
|
|
| Not yet recruiting | N/A | 238 | NA | surgical treatment, Conservative treatment | Shanghai 6th People's Hospital | Chest Trauma, Rib Fractures, Surgery--Complications | 06/23 | 06/24 | | |
SERIC-EVT, NCT04977869: Safety and Efficacy Study of Remote Ischemic Conditioning Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation |
|
|
| Completed | N/A | 498 | RoW | Remote ischemic conditioning, Sham remote ischemic conditioning | Yi Yang | Acute Ischemic Stroke | 09/24 | 09/24 | | |
NCT05598658: Effect of Remote Ischemic Conditioning on Cerebral Hemodynamics in Patients After Intravenous Thrombolysis (RICCH-IVT) |
|
|
| Completed | N/A | 100 | RoW | Remote ischemic conditioning, Sham remote ischemic conditioning | Yi Yang | Remote Ischemic Conditioning | 01/24 | 04/24 | | |
NCT05970653: Effect of RIC on Cerebral Autoregulation in Patients Undergoing Cerebrovascular Stent Implantation |
|
|
| Recruiting | N/A | 104 | RoW | Remote ischemic conditioning, Sham remote ischemic conditioning | Yi Yang | Remote Ischemic Conditioning | 05/24 | 08/24 | | |
NCT05843240: Effects of Repetitive Transcranial Magnetic Stimulation on Cerebral Autoregulation in Patients With Acute Ischemic Stroke |
|
|
| Recruiting | N/A | 128 | RoW | Repetitive transcranial magnetic stimulation, Sham repetitive transcranial magnetic stimulation | Yi Yang | Transcranial Magnetic Stimulation | 03/24 | 06/24 | | |
NCT05914623: Effects of High-frequency Repetitive Transcranial Magnetic Stimulation on Cerebral Autoregulation in Patients With Cerebral Small Vessel Disease |
|
|
| Recruiting | N/A | 80 | RoW | Repetitive transcranial magnetic stimulation, Sham repetitive transcranial magnetic stimulation | Yi Yang | Transcranial Magnetic Stimulation | 04/24 | 07/24 | | |
SERIC-EH, NCT03945305: Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension |
|
|
| Recruiting | N/A | 500 | RoW | Patients are treated with previous antihypertensive treatment plus remote ischemic conditioning., Previous antihypertensive treatment | Yi Yang | Essential Hypertension | 03/24 | 04/24 | | |
NCT05743101: Safety and Efficacy Study of Levofloxacin Combined With Endovascular Thrombectomy for Acute Ischemic Stroke |
|
|
| Not yet recruiting | N/A | 80 | NA | Levofloxacin, Endovascular thrombectomy, Levofloxacin simulant | Yi Yang | Acute Ischemic Stroke | 04/26 | 07/26 | | |
NCT05910242: Efficacy and Safety of Remote Ischemic Conditioning in the Treatment of Essential Hypertension (RICBP-EH) |
|
|
| Recruiting | N/A | 102 | RoW | Remote ischemic conditioning, Sham remote ischemic conditioning | Yi Yang | Essential Hypertension | 03/24 | 03/24 | | |
